Stockreport

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recur...

Precigen, Inc.  (PGEN) 
Last precigen, inc. earnings: 3/2 04:05 pm Check Earnings Report
PDF Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed in 86% of patients in Year 1, 91% in Year 2, and 95% in Year 3 No new safety ev [Read more]